Andere Kunden interessierten sich auch für
![Trends in Psychopharmacology: Pharmacodynamics to Pharmacogenetics]( "Trends in Psychopharmacology: Pharmacodynamics to Pharmacogenetics")
Trends in Psychopharmacology: Pharmacodynamics to Pharmacogenetics32,99 €![Clinical Pharmacology During Pregnancy]( "Clinical Pharmacology During Pregnancy")
Clinical Pharmacology During Pregnancy81,99 €![The Pharmacogenetics of Antidepressant Response]( "The Pharmacogenetics of Antidepressant Response")
The Pharmacogenetics of Antidepressant Response51,99 €![Principles of Pharmacogenetics and Pharmacogenomics]( "Principles of Pharmacogenetics and Pharmacogenomics")
Principles of Pharmacogenetics and Pharmacogenomics132,99 €![Serotonin]( "Serotonin")
Serotonin158,99 €![Clopidogrel Personalization: Pharmacogenetics and Pharmacometabonomics]( "Clopidogrel Personalization: Pharmacogenetics and Pharmacometabonomics")
Clopidogrel Personalization: Pharmacogenetics and Pharmacometabonomics32,99 €![The Serotonin Receptors]( "The Serotonin Receptors")
The Serotonin Receptors147,99 €
In 1987, the antidepressant drug Prozac© was
launched in the USA. Prozac© was the first of its
class - the class of SSRIs (selective serotonin
reuptake inhibitors). This new class of drugs was
considered to work miracles. It promised remission
from depression within two months with only minimal
side-effects. However, in recent years, reports of
SSRI-induced suicidality have begun to emerge and
there is a growing concern regarding the safety
profile of this class, especially in the pediatric
population. In 2004, the FDA presented reanalyzed
data demonstrating an increased risk of drug induced
suicidal behavioral (relative risk = 1.95). In other
words, people who take SSRIs are about twice as
likely to develop suicidal behavior compared with
those treated with placebo. The purpose of the work
presented in this book is to describe a method by
which a physician would be able, using a simple
blood test, to identify in advance those patients
who are not likely to respond well to an SSRI. This
in turn will be of great clinical utility, improve
patient satisfaction, improve risk-benefit ratio and
reduce the cost of mental health services.
launched in the USA. Prozac© was the first of its
class - the class of SSRIs (selective serotonin
reuptake inhibitors). This new class of drugs was
considered to work miracles. It promised remission
from depression within two months with only minimal
side-effects. However, in recent years, reports of
SSRI-induced suicidality have begun to emerge and
there is a growing concern regarding the safety
profile of this class, especially in the pediatric
population. In 2004, the FDA presented reanalyzed
data demonstrating an increased risk of drug induced
suicidal behavioral (relative risk = 1.95). In other
words, people who take SSRIs are about twice as
likely to develop suicidal behavior compared with
those treated with placebo. The purpose of the work
presented in this book is to describe a method by
which a physician would be able, using a simple
blood test, to identify in advance those patients
who are not likely to respond well to an SSRI. This
in turn will be of great clinical utility, improve
patient satisfaction, improve risk-benefit ratio and
reduce the cost of mental health services.